Advertisement

Reactions Weekly

, Volume 1769, Issue 1, pp 256–256 | Cite as

Infliximab

Infusion reaction: 2 case reports
Case report
  • 13 Downloads

Reference

  1. Van Hoeve K, et al. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring 41: 317-324, No. 3, Jun 2019. Available from: URL: http://doi.org/10.1097/FTD.0000000000000601 - BelgiumCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations